Document is current
Any future updates will be listed below
-
Authors
Nozawa, Kazuki
Sawaki, Masataka
Uemura, Yukari
Tsuneizumi, Michiko
Takano, Toshimi https://orcid.org/0000-0002-8417-5291
Gondo, Naomi
Hara, Fumikata
Harao, Michiko
Toyama, Tatsuya https://orcid.org/0000-0003-4713-7795
Taira, Naruto
Vivancos, Ana https://orcid.org/0000-0003-2888-6512
Perou, Charles M.
Sanfeliu, Esther
Brasó-Maristany, Fara
Parker, Joel S.
Buckingham, Wesley https://orcid.org/0009-0006-4707-9803
Paré, Laia
Villacampa, Guillermo
Marín-Aguilera, Mercedes
Villagrasa, Patricia
Prat, Aleix https://orcid.org/0000-0003-2377-540X
Iwata, Hiroji
- License Information
-
More Information
Article History
Received: 23 May 2025
Accepted: 17 October 2025
First Online: 4 November 2025
Competing interests
: G.V. has received speaker fees from MSD, Pfizer, GSK and Pierre Fabre, has held an advisory role with AstraZeneca, and received consultant fees from Reveal Genomics. AV reports personal fees from Bayer, Bristol Myers Squibb, Guardant Health, Merck, Novartis, Roche, and Incyte, outside the submitted work. F.B.M. has a patent PCT/EP2021/070788 (In vitro method for the prognosis of patients suffering from her2-positive breast cancer) licensed to Reveal Genomics. J.S.P., C.M.P. and A.P. are equity stockholders and consultants of Reveal Genomics. L.P. has a patent WO2018/103834 (Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy) licensed to Reveal Genomics. A.P. reports grants from Reveal Genomics during the conduct of the study, personal fees from Roche, and grants and personal fees from AstraZeneca, Daiichi Sankyo, and Novartis, outside the submitted work; in addition, A.P. has patent WO2018/103834 (Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy), PCT/EP2021/070788 (In vitro method for the prognosis of patients suffering from her2-positive breast cancer) licensed to Reveal Genomics. All other authors declare no competing interests.
